Association of Angiotensin Receptor Blockers with Incident Parkinson Disease in Patients with Hypertension: A Retrospective Cohort Study



      Angiotensin receptor blockers (ARBs), which are commonly used antihypertensives, have been proposed to lower the risk of Parkinson disease by reducing oxidative stress based on animal and in vitro studies. Thus, this study aimed to test this association in patients with newly diagnosed hypertension.


      This retrospective cohort study enrolled 107,207 patients with newly diagnosed hypertension between 2001 and 2013. The hazard ratios for Parkinson disease were calculated for ARB treatment compared with those who never used ARBs and among the 5 subgroups receiving different cumulative ARB dosages.


      We identified 527 (1.1%) Parkinson disease cases among patients with ARB treatment in a median observation period of 8.4 years compared to the 1,255 (2.2%) Parkinson disease cases among those without ARB treatment in a median observation period of 6.8 years. Overall, risk for developing Parkinson disease was statistically lower in the ARB-treated group with a hazard ratio of 0.56 (95% confidence interval: 0.51-0.63) than those without ARB.


      ARB treatment was associated with a statistically important reduction of Parkinson disease risk in patients with newly diagnosed hypertension. Therefore, ARB may constitute an effective neuroprotective strategy to lower Parkinson disease risk in such patients.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Balestrino R
        • Schapira AHV.
        Parkinson disease.
        Eur J Neurol. 2020; 27: 27-42
        • Hirsch EC
        • Vyas S
        • Hunot S.
        Neuroinflammation in Parkinson's disease.
        Parkinsonism Relat Disord. 2012; 18: S210-S212
        • Lee Y
        • Lee S
        • Chang SC
        • Lee J.
        Significant roles of neuroinflammation in Parkinson's disease: therapeutic targets for Parkinson's disease prevention.
        Arch Pharm Res. 2019; 42: 416-425
        • Puspita L
        • Chung SY
        • Shim JW.
        Oxidative stress and cellular pathologies in Parkinson's disease.
        Mol Brain. 2017; 10: 53
        • Nguyen Dinh Cat A
        • Touyz RM.
        A new look at the renin-angiotensin system–focusing on the vascular system.
        Peptides. 2011; 32: 2141-2150
        • Mertens B
        • Vanderheyden P
        • Michotte Y
        • Sarre S.
        The role of the central renin-angiotensin system in Parkinson's disease.
        J Renin Angiotensin Aldosterone Syst. 2010; 11: 49-56
        • Wright JW
        • Kawas LH
        • Harding JW.
        A role for the brain RAS in Alzheimer's and Parkinson's diseases.
        Front Endocrinol (Lausanne). 2013; 4: 158
        • Labandeira-García JL
        • Garrido-Gil P
        • Rodriguez-Pallares J
        • Valenzuela R
        • Borrajo A
        • Rodríguez-Perez AI.
        Brain renin-angiotensin system and dopaminergic cell vulnerability.
        Front Neuroanat. 2014; 8: 67
        • Chabrashvili T
        • Kitiyakara C
        • Blau J
        • et al.
        Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression.
        Am J Physiol Regul Integr Comp Physiol. 2003; 285: R117-R124
        • Rodriguez-Pallares J
        • Rey P
        • Parga JA
        • Muñoz A
        • Guerra MJ
        • Labandeira-Garcia JL.
        Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS.
        Neurobiol Dis. 2008; 31: 58-73
        • Perez-Lloret S
        • Otero-Losada M
        • Toblli JE
        • Capani F.
        Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease.
        Expert Opin Investig Drugs. 2017; 26: 1163-1173
        • Rey P
        • Lopez-Real A
        • Sanchez-Iglesias S
        • Muñoz A
        • Soto-Otero R
        • Labandeira-Garcia JL.
        Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons.
        Neurobiol Aging. 2007; 28: 555-567
        • Joglar B
        • Rodriguez-Pallares J
        • Rodriguez-Perez AI
        • Rey P
        • Guerra MJ
        • Labandeira-Garcia JL.
        The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease.
        J Neurochem. 2009; 109: 656-669
        • Mascolo A
        • Sessa M
        • Scavone C
        • et al.
        New and old roles of the peripheral and brain renin-angiotensin-aldosterone system (RAAS): Focus on cardiovascular and neurological diseases.
        Int J Cardiol. 2017; 227: 734-742
        • Lee YC
        • Lin CH
        • Wu RM
        • Lin JW
        • Chang CH
        • Lai MS.
        Antihypertensive agents and risk of Parkinson's disease: a nationwide cohort study.
        PLoS One. 2014; 9: e98961
        • Becker C
        • Jick SS
        • Meier CR.
        Use of antihypertensives and the risk of Parkinson disease.
        Neurology. 2008; 70: 1438-1444
        • Ritz B
        • Rhodes SL
        • Qian L
        • Schernhammer E
        • Olsen JH
        • Friis S.
        L-type calcium channel blockers and Parkinson disease in Denmark.
        Ann Neurol. 2010; 67: 600-606
        • Qiu C
        • Hu G
        • Kivipelto M
        • et al.
        Association of blood pressure and hypertension with the risk of Parkinson disease: the National FINRISK Study.
        Hypertension. 2011; 57: 1094-1100
        • Chen J
        • Zhang C
        • Wu Y
        • Zhang D.
        Association between hypertension and the risk of Parkinson's disease: a meta-analysis of analytical studies.
        Neuroepidemiology. 2019; 52: 181-192
        • Ascherio A
        • Tanner CM.
        Use of antihypertensives and the risk of Parkinson disease.
        Neurology. 2009; 72: 578-579
        • Labandeira-Garcia JL
        • Rodriguez-Pallares J
        • Dominguez-Meijide A
        • Valenzuela R
        • Villar-Cheda B
        • Rodriguez-Perez AI.
        Dopamine-angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease.
        Mov Disord. 2013; 28: 1337-1342
        • Allen AM
        • MacGregor DP
        • Chai SY
        • et al.
        Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia.
        Ann Neurol. 1992; 32: 339-344
        • Brichta L
        • Greengard P.
        Molecular determinants of selective dopaminergic vulnerability in Parkinson's disease: an update.
        Front Neuroanat. 2014; 8: 152
        • Pacelli C
        • Giguère N
        • Bourque MJ
        • Lévesque M
        • Slack RS
        • Trudeau L.
        Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons.
        Curr Biol. 2015; 25: 2349-2360
        • Surmeier DJ
        • Obeso JA
        • Halliday GM.
        Selective neuronal vulnerability in Parkinson disease.
        Nat Rev Neurosci. 2017; 18: 101-113
        • Trist BG
        • Hare DJ
        • Double KL.
        Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease.
        Aging Cell. 2019; 18: e13031
        • Labandeira-Garcia JL
        • Rodriguez-Pallares J
        • Rodriguez-Perez AI
        • et al.
        Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease.
        Am J Neurodegener Dis. 2012; 1: 226-244
        • Steckelings UM
        • Kaschina E
        • Unger T.
        The AT2 receptor–a matter of love and hate.
        Peptides. 2005; 26: 1401-1409
        • Ascherio A
        • Schwarzschild MA.
        The epidemiology of Parkinson's disease: risk factors and prevention.
        Lancet Neurol. 2016; 15: 1257-1272
        • van der Holst HM
        • van Uden IWM
        • Tuladhar AM
        • et al.
        Cerebral small vessel disease and incident parkinsonism.
        Neurology. 2015; 85: 1569-1577
        • Hakim AM.
        Small vessel disease.
        Front Neurol. 2019; 10: 1020